MXPA06011218A - Uso de agonistas del receptor delta activado por el proliferador de peroxisoma para el tratamiento de esclerosis multiple y otras enfermedades de desmielinizacion. - Google Patents
Uso de agonistas del receptor delta activado por el proliferador de peroxisoma para el tratamiento de esclerosis multiple y otras enfermedades de desmielinizacion.Info
- Publication number
- MXPA06011218A MXPA06011218A MXPA06011218A MXPA06011218A MXPA06011218A MX PA06011218 A MXPA06011218 A MX PA06011218A MX PA06011218 A MXPA06011218 A MX PA06011218A MX PA06011218 A MXPA06011218 A MX PA06011218A MX PA06011218 A MXPA06011218 A MX PA06011218A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- compound
- ppar
- disease
- invitrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55853304P | 2004-04-01 | 2004-04-01 | |
| PCT/US2005/010371 WO2005097098A2 (en) | 2004-04-01 | 2005-03-29 | Use of ppr delta agonists for treating demyelinating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06011218A true MXPA06011218A (es) | 2007-01-16 |
Family
ID=34977094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06011218A MXPA06011218A (es) | 2004-04-01 | 2005-03-29 | Uso de agonistas del receptor delta activado por el proliferador de peroxisoma para el tratamiento de esclerosis multiple y otras enfermedades de desmielinizacion. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070149580A1 (https=) |
| EP (1) | EP1737440A2 (https=) |
| JP (1) | JP2007530703A (https=) |
| KR (1) | KR20060134191A (https=) |
| CN (1) | CN1950077A (https=) |
| AU (1) | AU2005231358A1 (https=) |
| BR (1) | BRPI0509540A (https=) |
| CA (1) | CA2561159A1 (https=) |
| IL (1) | IL178165A0 (https=) |
| MA (1) | MA28561B1 (https=) |
| MX (1) | MXPA06011218A (https=) |
| NO (1) | NO20064985L (https=) |
| RU (1) | RU2006138495A (https=) |
| SG (1) | SG138623A1 (https=) |
| WO (1) | WO2005097098A2 (https=) |
| ZA (1) | ZA200607850B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005024384D1 (de) | 2004-05-05 | 2010-12-09 | High Point Pharmaceuticals Llc | Neue verbindungen, ihre herstellung und verwendung |
| US8053598B2 (en) | 2004-05-05 | 2011-11-08 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
| ES2372617T3 (es) | 2005-06-30 | 2012-01-24 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de ppar-delta. |
| EP1964575B1 (en) * | 2005-11-28 | 2015-09-23 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical comprising ppar agonist |
| CN103224477A (zh) | 2005-12-22 | 2013-07-31 | 高点制药有限责任公司 | 作为PPAR-δ活化剂的苯氧基乙酸 |
| US7943612B2 (en) | 2006-03-09 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds that modulate PPAR activity, their preparation and use |
| US8716317B2 (en) | 2008-06-09 | 2014-05-06 | Sanofi | Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| US8329725B2 (en) | 2008-06-09 | 2012-12-11 | Sanofi | Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| EP2483406A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
| KR20120107113A (ko) | 2009-12-17 | 2012-09-28 | 사노피 | 수초 염기성 단백질 프로모터(ｍｂｐ-ｌｕｃｉ)의 조절 하에 루시페라제를 발현하는 동물 모델 및 생물발광 생체내 영상화를 위한 상기 동물 모델의 용도 |
| JP6133790B2 (ja) * | 2011-02-18 | 2017-05-24 | ザ スクリプス リサーチ インスティテュート | ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化 |
| EP3756661A1 (en) | 2013-09-09 | 2020-12-30 | vTv Therapeutics LLC | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2021092279A1 (en) * | 2019-11-06 | 2021-05-14 | Board Of Regents, The University Of Texas System | Methods for the treatment of dysmyelinating/demyelinating diseases |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1856997A (en) * | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| AU2001288271A1 (en) * | 2000-08-17 | 2002-02-25 | Harrihar A. Pershadsingh | Methods for treating inflammatory diseases |
| GB0024362D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| GB0024361D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| WO2004082621A2 (en) * | 2003-03-15 | 2004-09-30 | Bethesda Pharmaceuticals, Inc. | Novel ppar agonists, pharmaceutical compositions and uses thereof |
| JPWO2004093910A1 (ja) * | 2003-04-22 | 2006-07-13 | アステラス製薬株式会社 | ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤 |
-
2005
- 2005-03-29 WO PCT/US2005/010371 patent/WO2005097098A2/en not_active Ceased
- 2005-03-29 RU RU2006138495/14A patent/RU2006138495A/ru not_active Application Discontinuation
- 2005-03-29 SG SG200800123-2A patent/SG138623A1/en unknown
- 2005-03-29 KR KR1020067022955A patent/KR20060134191A/ko not_active Withdrawn
- 2005-03-29 CA CA002561159A patent/CA2561159A1/en not_active Abandoned
- 2005-03-29 JP JP2007506442A patent/JP2007530703A/ja not_active Abandoned
- 2005-03-29 BR BRPI0509540-9A patent/BRPI0509540A/pt not_active IP Right Cessation
- 2005-03-29 EP EP05729215A patent/EP1737440A2/en not_active Withdrawn
- 2005-03-29 MX MXPA06011218A patent/MXPA06011218A/es not_active Application Discontinuation
- 2005-03-29 CN CNA2005800148506A patent/CN1950077A/zh active Pending
- 2005-03-29 AU AU2005231358A patent/AU2005231358A1/en not_active Abandoned
-
2006
- 2006-09-18 IL IL178165A patent/IL178165A0/en unknown
- 2006-09-19 ZA ZA200607850A patent/ZA200607850B/xx unknown
- 2006-09-26 US US11/535,240 patent/US20070149580A1/en not_active Abandoned
- 2006-10-31 MA MA29427A patent/MA28561B1/fr unknown
- 2006-10-31 NO NO20064985A patent/NO20064985L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005097098A2 (en) | 2005-10-20 |
| BRPI0509540A (pt) | 2007-09-18 |
| CN1950077A (zh) | 2007-04-18 |
| KR20060134191A (ko) | 2006-12-27 |
| JP2007530703A (ja) | 2007-11-01 |
| ZA200607850B (en) | 2008-10-29 |
| IL178165A0 (en) | 2008-03-20 |
| EP1737440A2 (en) | 2007-01-03 |
| CA2561159A1 (en) | 2005-10-20 |
| NO20064985L (no) | 2006-10-31 |
| WO2005097098A3 (en) | 2005-12-22 |
| RU2006138495A (ru) | 2008-05-10 |
| US20070149580A1 (en) | 2007-06-28 |
| MA28561B1 (fr) | 2007-04-03 |
| SG138623A1 (en) | 2008-01-28 |
| AU2005231358A1 (en) | 2005-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Hes1 but not Hes5 regulates an astrocyte versus oligodendrocyte fate choice in glial restricted precursors | |
| MXPA06011218A (es) | Uso de agonistas del receptor delta activado por el proliferador de peroxisoma para el tratamiento de esclerosis multiple y otras enfermedades de desmielinizacion. | |
| EP3721880B1 (en) | Composition and method for muscle repair and regeneration | |
| US20150119327A1 (en) | Drug screening platform for rett syndrome | |
| EP2806948B1 (en) | Method for enhancing remyelination using gli1 inhibitors | |
| Jana et al. | Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-β | |
| WO2015069736A1 (en) | METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS | |
| US7132287B2 (en) | Method for neural stem cell differentiation using 5HT-1A agonists | |
| US20170196839A1 (en) | Neurodegenerative diseases and methods of modeling | |
| Jana et al. | IL‐12 p40 homodimer, the so‐called biologically inactive molecule, induces nitric oxide synthase in microglia via IL‐12Rβ1 | |
| Yao et al. | In vitro and in vivo induction and activation of nNOS by LPS in oligodendrocytes | |
| US20040092010A1 (en) | Method of proliferating and inducing brain stem cells to differentiate to neurons | |
| Timmer et al. | The activin signaling pathway promotes differentiation of dI3 interneurons in the spinal neural tube | |
| EP3615022B1 (en) | Small organic molecules for use in the treatment of neuroinflammatory disorders | |
| US20210186903A1 (en) | Treatment for demyelinating disease | |
| HK40080448B (en) | Retinoic acid receptor gamma agonists for muscle repair and regeneration | |
| HK40036876A (en) | Composition and method for muscle repair and regeneration | |
| HK40036876B (en) | Composition and method for muscle repair and regeneration | |
| HK40080448A (en) | Retinoic acid receptor gamma agonists for muscle repair and regeneration | |
| Li | The mechanisms of ethanol-induced damage to the developing cerebellum: Effects on the cerebellar granule cells | |
| Van Heyningen | Control of glial progenitor cell number in the developing central nervous system | |
| Redwine | The in vivo PDGF response during remyelination in mouse spinal cord following murine hepatitis virus strain A59-induced transient demyelination | |
| HK1102384A (en) | Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases | |
| AU2015200760A1 (en) | Composition and method for muscle repair and regeneration | |
| WO1999066073A1 (fr) | PROCEDE DE CRIBLAGE D'AGENT DE POTENTIALISATION DU GENE Pax ET COMPOSITIONS MEDICINALES POUR LA POTENTIALISATION DU GENE Pax |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |